Once crypto miners, IREN and Applied Digital have pivoted to AI infrastructure, delivering staggering returns. But as valuations soar, investors face a critical choice between predictable cash flow and high-growth optionality.
Amidst market volatility, Coca-Cola (KO) stands out with its formidable brand moat and a 63-year dividend growth streak, offering investors a blend of stability and reliable income.
The Horatio Alger Award bestowed upon ResMed founder Dr. Peter Farrell underscores the company's decades-long leadership in sleep and respiratory care, bringing its financial performance and competitive strategy into sharper focus for investors.
Cisco Systems has inked a major 15-year virtual power purchase agreement for solar energy in Poland, a move that extends its environmental commitments into one of Europe's more fossil-fuel-dependent grids and underscores its long-term capital allocation strategy beyond core tech.
Mitsubishi Corporation and U.S.-based Aethon Energy have announced a strategic global alliance aimed at co-developing projects across liquefied natural gas (LNG), carbon capture, geothermal energy, and digital infrastructure, marking a significant step in the Japanese conglomerate's lower-carbon expansion.
A fresh round of analyst price target adjustments for European asset manager Amundi (ENXTPA:AMUN) is prompting investors to recalibrate their expectations, placing renewed scrutiny on the firm's growth trajectory in a challenging macroeconomic climate.
Standex International Corporation reported robust fiscal second-quarter results, with revenue climbing to $221.32 million and net income reaching $2.12 million. The company raised its quarterly dividend by 6.3% and issued an upbeat forecast for the third quarter, reinforcing confidence in its strategic shift toward high-value engineered products.
Blue Owl Capital faces a wave of securities class actions alleging disclosure failures around liquidity and redemptions, casting a shadow over its robust alternative asset management platform. As legal pressures mount, the market weighs solid analyst backing against growing governance concerns, setting the stage for a pivotal earnings report.
Cardinal Energy Ltd. (TSX:CJ) has successfully upsized its bought deal financing to CA$95.15 million, capitalizing on robust investor appetite. The proceeds are earmarked to accelerate development of its key Reford 2 thermal oil project and strengthen its balance sheet, even as its valuation metrics present a complex picture for investors.
Visa's fiscal first-quarter earnings surpassed expectations, driven by robust cross-border transactions and a surge in high-margin digital services. The payments giant signals confidence in sustained consumer resilience despite some moderation in U.S. debit volumes.
Thermo Fisher Scientific reported a strong finish to 2025, with Q4 results exceeding expectations. While navigating currency volatility and tariffs, the life sciences giant highlighted growth in core biopharma sectors, strategic acquisitions like Clario, and a solid 2026 outlook.
Trane Technologies (NYSE: TT) reported robust Q4 2025 results, driven by exceptional commercial HVAC demand and a record $7.8 billion backlog. While proactive inventory adjustments pressured residential margins, executives project 12-14% adjusted EPS growth for 2026, fueled by strategic acquisitions and sustained commercial strength.
The medical technology giant reported double-digit organic sales growth and robust profitability for 2025, driven by record installations of its Mako surgical robots. While projecting continued strength for 2026, management acknowledged incremental tariff pressures but expressed confidence in the company's ability to sustain margin expansion.
Bank of America Securities has reaffirmed its Buy rating on Hesai Group (HSAI), raising its price target to $32, citing the lidar maker's technological milestones, strategic partnership with NVIDIA, and favorable regulatory developments for autonomous driving.
Swiss banking giant UBS has initiated coverage on Zai Lab Limited (NASDAQ: ZLAB) with a bullish 'Buy' rating and a $35 price target, highlighting the biopharma firm's strategic pivot from a China-focused player to a burgeoning global innovation platform with a promising proprietary pipeline.
Brokerage firm CLSA initiates coverage on Atour Lifestyle Holdings with an 'Outperform' rating and a $49 price target, highlighting its unique brand ecosystem and asset-light model as key differentiators in a competitive market.
Despite a mixed analyst outlook, Morgan Stanley projects robust growth for Full Truck Alliance's core commission business, even as overall revenue faces headwinds. The digital freight platform's long-term strategy is gaining favor.
While Morgan Stanley maintains an Overweight rating on PDD Holdings, the firm has removed the e-commerce giant from its Top Picks list, citing heightened regulatory scrutiny and a slower-than-expected consumer recovery in China.
H.C. Wainwright has trimmed its price target on Genmab following mixed Phase 3 results for its lymphoma drug EPKINLY, though maintains a Buy rating, citing precedent and ongoing trials.
Citizens reiterates a 'Market Outperform' rating and $396 price target for BeOne Medicines (ONC), driven by robust Phase 3 trial results in gastric cancer. The firm highlights the company's strong pipeline and cash position as key growth drivers.
